Evidence map›Paper›PMID 42830321›Full record

ArticleNature communications2026

Gastric cancer tertiary lymphoid structures in the muscularis propria are associated with therapy resistance and promote immunosuppression.

Yan Meng, Meng Wang, Manmei Long, Yantao Duan, Jingwu Yue, Delin Zou, Weihong Zhang, Mingquan Li, Ruixian Yu, Lin Shao and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Yan Meng *State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China. karenmeng0521@163.com.ORCID 0009-0009-4240-3282
Meng Wang *State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-5488-1726
Manmei Long *Department of Pathology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yantao Duan *Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0003-0786-1797
Jingwu YueState Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
Delin ZouState Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
Weihong ZhangDepartment of Oncology, Shanghai Tenth People's Hospital, Department of Biochemistry and Molecular Biology, Tongji University School of Medicine, Shanghai, China.
Mingquan LiState Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
Ruixian YuDepartment of General Surgery, QingPu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, China.
Lin ShaoState Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
Xinyu YangState Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
Yi HanDepartment of Oncology, Shanghai Tenth People's Hospital, Department of Biochemistry and Molecular Biology, Tongji University School of Medicine, Shanghai, China.
Wenjia WangState Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-2892-6214
Jianfeng ChenState Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
Miao HeState Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-0731-6801
Yang TangDepartment of Oncology, Shanghai Tenth People's Hospital, Department of Biochemistry and Molecular Biology, Tongji University School of Medicine, Shanghai, China.
Zongwei ChenDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Wei KangDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, State Key Laboratory of Digestive Disease, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0002-4651-677X
Ka Fai ToDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, State Key Laboratory of Digestive Disease, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0003-4919-3707
Zhaocai ZhouState Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China. zhouzhaocai@fudan.edu.cn.ORCID 0000-0002-5441-3922
Dazhi XuDepartment of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. xudzh@shca.org.cn.ORCID 0000-0002-2265-1272
Hui LiDepartment of Gastrointestinal Cancer Biology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin, China. lihui@tjmuch.com.ORCID 0000-0002-3526-6664
Shi JiaoState Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China. jiaoshi@fudan.edu.cn.ORCID 0000-0003-3591-8973

Funding

National Science Foundation of China | Key Programme 2020YFA0803200National Science Foundation of China | Key Programme 2023YFC2505903
6 · The paper itself

Abstract

Tertiary lymphoid structures (TLS) are local immune microenvironments within tumors housing T cells and B cells, are often coordinating anti-tumor immunity and associated with better responses to immunotherapy. Here, we use H&E morphological assessment and multiplex immunofluorescence to analyze surgical tumor specimens from 71 patients with gastric cancer (GC) after treatment with neoadjuvant anti-PD-1 therapy, chemotherapy, and subsequent gastrectomy. We find increased TLS density and area in the muscularis propria of treatment-resistant GCs. These muscularis TLS are structurally and functionally impaired, with increased naïve B cell presence but reduced germinal center B cell infiltration. Mechanistically, PLA2G2A

Indexed as

Drug Resistance, NeoplasmStomach NeoplasmsTertiary Lymphoid StructuresAnimalsB-LymphocytesCancer-Associated FibroblastsCell DifferentiationCell Line, TumorFemaleGastric MucosaHumansImmunotherapyMaleTumor Microenvironment

Identifiers

PMID42830321
PMCPMC13635219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.